Iovance Biotherapeutics
IOVA
263 hedge funds and large institutions have $715M invested in Iovance Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 103 increasing their positions, 63 reducing their positions, and 36 closing their positions.
103% more call options, than puts
Call options by funds: $12M | Put options by funds: $5.94M
63% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 63
55% more capital invested
Capital invested by funds: $462M → $715M (+$253M)
42% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 36
7.02% more ownership
Funds ownership: 58.87% → 65.89% (+7%)
4% more funds holding
Funds holding: 253 → 263 (+10)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$18.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$15.9M |
| 3 |
HF
HRT Financial
New York
|
+$9.22M |
| 4 |
D.E. Shaw & Co
New York
|
+$8.68M |
| 5 |
Morgan Stanley
New York
|
+$8.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
-$6.94M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.97M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.19M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.12M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2M |
IOVA Hedge Fund Activity: Q4 2025 in Review
263 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2025, worth a combined $715M — up 55% from $462M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new IOVA positions and 36 closed out — a net gain of 15 holders — while 103 added to existing stakes and 63 trimmed.
The largest buyer was Bank of America, adding an estimated $18.5M. The largest seller was Principal Financial Group, cutting an estimated $6.94M.
- 263 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2025, up from 253 in Q3 2025.
- Funds reported $715M of Iovance Biotherapeutics stock for Q4 2025, up 55% quarter-over-quarter.
- 51 funds opened new Iovance Biotherapeutics positions in Q4 2025 and 36 closed out, a net change of +15 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2025 was Bank of America, an estimated $18.5M added.
- The largest Iovance Biotherapeutics seller in Q4 2025 was Principal Financial Group, an estimated $6.94M sold.
Based on aggregated 13F filings for Q4 2025.